Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Dr. Charlotte Jones-Burton, Vice-President, Global Clinical Development, Nephrology, Otsuka Pharmaceutical Development & Commercialization, Inc. who is dedicated to creating healthier communities globally through drug development, patient advocacy and people engagement / empowerment
As a physician scientist, I have dedicated my life’s work to creating healthier communities globally through drug development, advocacy, empowerment and engagement. Born in a rural, segregated Arkansas town of 18,000 people, many lived below the poverty line — both then and now — regardless of race. I witnessed the impact that social determinants (i.e. where people are born, live, go to school, work) can have on the health of communities. Many in my community and family suffered from chronic diseases and I knew that when I grew up, I wanted to make a difference in their lives.
Now as a pharmaceutical executive with significant experience leading clinical trial development for multiple medicines, I can combine my leadership in research and development with my clinical acumen to positively impact the lives of patients and communities who suffer with chronic diseases. But in the wake of this year’s racial and health horrors, I have to ask myself: is my leadership enough?
After leading an organization through the first half of 2020 during both the COVID-19 pandemic and horrific killings of Black Americans (Ahmaud Arbery, Breonna Taylor and George Floyd), I believe that the pharmaceutical industry can and needs to do more to advance the health of patients and make a positive impact on people’s lives.
Particularly, access to clinical trials and to approved medicines are two critical ways the pharmaceutical industry can positively impact the health of patients and communities. Racial disparities are well documented for both clinical trials and access to treatments. There is an opportunity today for the pharmaceutical industry to take bold action to rectify these inequities.
What would it take for the pharmaceutical industry to improve the care for the patients who we serve, particularly through the medicines we develop? There is a three-pronged approach that reflects my personal opinion and values of community, service and health and wellness.
- Ensure that there is appropriate representation. The pharmaceutical industry is one of many dealing with a lack of representation within their companies, particularly in higher levels where decisions are made. It is well documented that companies with greater representation in gender and racial diversity perform better than those with lower representation. Inclusion of Black, Latinx and other diverse leaders in all areas of business, from the discovery labs to approved medicines, is critical. Importantly, external scientific and strategic advisors, investigators and vendors should also be diverse and included throughout the medicine development pipeline. By developing products with the lens of diversity, we are better suited to welcome all populations to benefit from the medicines and treatments that the industry provides.
- Understand how to meet the needs of underserved patients. Having a diverse workforce can also offer insights on how to engage with communities who are diverse. Pharmaceutical companies — through diverse workforce, advisors, investigators and vendors — can bring those insights and support for communities to educate, drive trust and listen to the concerns of Black, Latinx and other diverse communities. We need to follow the lead of other industries who connect with individuals in the communities they serve to better understand how their products work, how they are used, how they can be improved and how they can better meet the needs of their target audience. Representatives within the pharmaceutical industry have the responsibility to recognize this and help ensure that we are all working together to deliver the best medicines and care to all people.
- Make clinical trials more equitable. Having diverse populations in clinical trials is critical as it provides the ability to help address inequities in health and understand the impact of medication on diverse populations. However, the needle has not moved much in this area in decades. Within the U.S., there are centuries of abuse, inappropriate medical care and other blatantly racist acts that have impacted the relationship between medical researchers and communities of color. Terrible historical events, such as Tuskegee, have created aversions for people of color to enroll into modern clinical trials. We consistently see underrepresentation of minorities in clinical trials, even in those trials where people of color bear a higher burden of disease, such as particular cardiovascular conditions. To rectify this inequity, a foundation of trust must be built with populations of color. This can be done through building relationships with physician groups and patient advocacy organizations to create and support community education, develop relationships with community leaders and hear trusted voices’ views on health and wellness in those communities. Committing to an intentional process to ensure diversity both internally and externally will not only strengthen the industry but will promote the health of all communities.
Now is the time where we, as representatives of the pharmaceutical industry, must hold a mirror up to ourselves and answer the difficult question: Are we living out our mission and ensuring better health for ALL?
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Staffing up: Building the future biopharma workforce to keep America in the lead
Nearly 80 researchers advocate on Capitol Hill
Congratulations to our 2026 Working for Cures Employee Champions
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
Bringing to life the full story of biopharmaceutical innovation and investments
From sound to science: How IP powers innovation in music and hearing
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
Congratulations to our 2024 Working for Cures Employee Champions
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
The importance of partnership: A conversation with Takeda
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
New research: American biopharmaceutical investment in R&D drives transformational innovation
The future of oncology R&D lies in policymakers’ hands
More than 60 researchers advocate on Capitol Hill
Alzheimer's & Brain Awareness Month: A conversation with Biogen
Alzheimer's & Brain Awareness Month: A conversation with Eisai
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
Congratulations to our 2023 Working for Cures Employee Champions
Watch: Putting patients front and center for World AIDS Day
New Report: 1,600 cancer treatments and vaccines in clinical development
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
Watch: New video series spotlights advances in biopharmaceutical science
Between hope and despair: Improving cancer outcomes
New report shows high-impact R&D happens after cancer medicines are first approved
More than 60 researchers ask Congress to support innovation
Biopharmaceutical science powered by PRIDE
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
World IP Day 2023: Celebrating women leaders in innovation
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
What we’ve learned from three years of fighting COVID-19
WTAS: Inflation Reduction Act already impacting R&D decisions
Using traditional HTAs to determine coverage threatens patient access to medicine
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
Traditional HTAs keep diverse patients out of the conversation
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
Congratulations to our 2022 Working for Cures Employee Champions
Traditional HTA methods treat everyone like the “average” patient
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
An open letter to Congress: Stand with patients and future cures
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Biopharmaceutical researchers to discuss the value of R&D with Congress
Potential gene therapies bring hope to patients with sickle cell disease
A conversation with Barry Greene, CEO of Sage Therapeutics
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Biopharmaceutical industry drives economic growth in all 50 states
Guest post: Joining forces to combat the COVID-19 mental health crisis
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
Industry leaders discuss the impact of the drug pricing debate
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Researchers to shine light on biopharmaceutical R&D with policymakers
PhRMA hosts first stakeholder workshop on clinical trial diversity
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
PhRMA member companies share how they are improving clinical trial diversity
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Guest Post: Bringing our best to the fight against COVID-19
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Just released: PhRMA members’ new clinical trial diversity principles
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Sharing rebates can improve access to medicines and increase health equity
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
PhRMA member companies invested $83 billion in research and development last year
PhRMA will continue to advocate for equity within our industry
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Systemic racism is as real as any disease, and our industry is not immune
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
New report explores setbacks that bring future cancer success stories
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
PhRMA awards $100,000 to fund projects that address health inequalities
Guest Post: What will we learn from COVID-19?
Observing National Minority Health Month in the age of COVID-19
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
To the millions affected by COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Working together to combat coronavirus
The journey to better health care requires a holistic view
Helping those affected by the 2017 hurricane season
Celebrating PRIDE in biopharmaceutical science
Guest Post: The importance of a modern FDA in drug discovery
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
Three ways the pharmaceutical industry can positively impact health equity
PhRMA Member Company
Health Equity
Three ways the pharmaceutical industry can positively impact health equity
Three ways the pharmaceutical industry can positively impact health equity